Crystalline n-methyl tryptamine derivatives

Abstract

Crystalline N-methyl tryptamine derivatives, compositions containing those crystalline forms and their methods of use are disclosed. The crystalline N-methyl tryptamine derivatives according to the invention include crystalline N-methyl-N-propyltryptamine (MPT), crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate), crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate), and crystalline [2-(1H-indol-3-yl)ethyl]trimethylazanium iodide (N,N,N-trimethyltryptammonium iodide or TMT iodide), such as crystalline form 1 of TMT iodide.

Dependencies are inferred from the claim text.